Safety and Efficacy of Filgotinib for Japanese Patients with RA and Inadequate Response to MTX: FINCH 1 52-Week Results and FINCH 4 48-Week Results.
Sign Up to like & getrecommendations! Published in 2022 at "Modern rheumatology"
DOI: 10.1093/mr/roac084
Abstract: OBJECTIVE To present safety and efficacy of the JAK1 preferential inhibitor filgotinib in Japanese patients with prior inadequate response (IR) to methotrexate (MTX) from a 52-week randomised controlled parent study (PS) and long-term extension (LTE)… read more here.
Keywords: finch week; rheumatology; safety; japanese patients ... See more keywords